Companies: 10,795·Total market cap: $144.5T
Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

ARWRNASDAQHealthcare● Active
$73.09
$-2.07(-2.75%)
Market Cap$10.3B
P/E Ratio
52W High$82.26
52W Low$14.3

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

arwr · stock forecast · 20 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 20 Wall Street analysts in the past 3 months

SellBuy

Buy

20 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
15
Hold
5
Sell
0
Strong Sell
0
Total: 20 · Buy rate: 75.0%

12-Month Price Target

High

$110

Consensus

$83.56

+14.3% upside

Low

$35.00

Median: $90 · Last Close: $73.09

The Arrowhead Pharmaceuticals, Inc. (ARWR) analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month ARWR price target is $83.56, representing +14.3% upside from the current price of $73.09.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $84 (14.3%)

Consensus Target

$83.56

14.3% upside

High Target

$110

50.5%

Low Target

$35

-52.1%

Current Price

$73.09

as of today

Based on analyst price targets, the ARWR stock price prediction for the next 12 months ranges from $35 to $110. The consensus ARWR price forecast of $83.56 implies 14.3% upside from the current price of $73.09.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$70.813.12%

1-day model range: $70.36–$71.26. Peak: $71.26 (-3.12%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$99+35.7%
2028$122+67.2%
2029$141+92.4%
2030$154+111.2%
2031+124.7%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%7%43%
7Buy
1Neutral
6Sell
RSI (14)43.7Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ARWR · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$73.36SELL
MA 10$75.64SELL
MA 20$76.00SELL
MA 50$71.46BUY
MA 100$67.32BUY
MA 200$55.68BUY
Current $ARWR · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$74.02SELL
EMA 10$74.82SELL
EMA 20$74.96SELL
EMA 50$72.05BUY
EMA 100$66.91BUY
EMA 200$57.00BUY
Current $ARWR · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Bernstein2026-05-13
Maintains
Market PerformMarket Perform
RBC Capital2026-05-08
Maintains
OutperformOutperform
Morgan Stanley2026-04-21
Upgrade ↑
Equal WeightOverweight
HC Wainwright & Co.2026-03-25
Maintains
BuyBuy
HC Wainwright & Co.2026-02-10
Maintains
BuyBuy
B. Riley Securities2026-01-22
Maintains
BuyBuy
HC Wainwright & Co.2026-01-21
Maintains
BuyBuy
Piper Sandler2026-01-13
Maintains
OverweightOverweight
Chardan Capital2026-01-07
Maintains
BuyBuy
Goldman Sachs2026-01-07
Maintains
NeutralNeutral

Wall Street analysts have recently issued updated ratings on Arrowhead Pharmaceuticals, Inc. (ARWR) stock. Of the recent 154 rating actions, 13 were upgrades and 12 were downgrades. 20 analysts currently cover ARWR.

Analyst Recommendation Trends

Buy ratings615
Hold ratings01↑ +1
Sell ratings00

ARWR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$449M

↓ 25.4% YoY

Revenue Next Year

$353M

↓ 21.2% YoY

EPS This Year

$-3.12

EPS Next Year

$-3.90

↑ 24.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ARWR EPS of $-3.12 for the current fiscal year, based on estimates from 11 analysts. The ARWR revenue forecast is $449M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ARWR stock forecast is supported by two independent data sources: analyst consensus ratings from 20 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ARWR price target is $83.56 (+14.3% upside), with an analyst consensus of Buy.

The ARWR short-term stock prediction for tomorrow is $70.81 (-3.12%). The ARWR stock price prediction for 2027 estimates an average of $99. The ARWR stock prediction for 2030 projects a range of $144–$165.

Arrowhead Pharmaceuticals, Inc. trades on NASDAQ under the ticker ARWR. The ARWR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ARWR forecast · 8 questions

According to 20 Wall Street analysts, the average 12-month ARWR price target is $83.56, with a high forecast of $110.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +14.3% potential upside from the current price of $73.09.

ARWR price targetWhat is ARWR price targetARWR analyst price targetARWR 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.